Evidence map›Paper›PMID 41972422›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Dual-Physical-Field Nanocatalysis: Injectable Hydrogel Enables Piezo-Photothermal Synergy for Breast Cancer Therapy.

Can Tian, Shihan Xiao, Xuan Chen, Danni Zhang, Zizhen Liu, Jing Wang, Ning Xie, Wei Li

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Can TianDepartment of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China.
Shihan XiaoDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, University of South China, Hengyang, China.
Xuan ChenDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, University of South China, Hengyang, China.
Danni ZhangDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, University of South China, Hengyang, China.
Zizhen LiuDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, University of South China, Hengyang, China.
Jing WangDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, University of South China, Hengyang, China.
Ning XieDepartment of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China.
Wei LiDepartment of Breast and Thyroid Surgery, The Second Affiliated Hospital, University of South China, Hengyang, China.ORCID https://orcid.org/0000-0002-6557-3948

Funding

Beijing Science and Technology Innovation Medical Development Foundation KC2023-JX-0082-05China Primary Health Care Foundation cphcf-2023-056Climb Plan of Hunan Cancer Hospital ZX2021005Hunan Cancer Hospital's Qihang Youth Fund QH2023011Hunan Provincial Key Laboratory of Basic and Clinical Pharmacological Research on Gastrointestinal Tumors 2023TP1014Hunan Provincial Natural Science Foundation of China 2025JJ80824Key Project of Hunan Provincial Department of Education 24A0289Natural Science Foundation of Hunan Province for Young Researchers 2025JJ60589
6 · The paper itself

Abstract

Piezocatalytic therapy (PCT) harnesses mechanical energy to generate tumor-lethal reactive oxygen species (ROS), but its efficacy is limited by rapid electron-hole recombination and poor intratumoral retention. To overcome these limitations, we engineered heterostructured BiOCl@CuO nanosheets embedded in an injectable, conductive, thermosensitive hydrogel composed of Pluronic F127 (F127) and reduced graphene oxide (rGO), with rGO specifically enhancing the hydrogel's mechanical strength and conductivity, for the combinational treatment of breast cancer. Under ultrasound (US) stimulation, BiOCl@CuO establishes a strong interfacial electric field that enhances charge separation and accelerates the generation of ROS. In addition, near-infrared (NIR) irradiation activates BiOCl@CuO to convert light into heat, elevating intratumoral temperature and further amplifying ROS-mediated cytotoxicity while enabling photothermal therapy (PTT). The integrated BiOCl@CuO/F127@rGO hydrogel exhibits rapid sol-gel transition at physiological temperature, robust tissue adhesion, and sustained local retention. In vitro, the synergistic therapy induced marked ROS bursts and achieved 60% breast cancer cell ablation at 50 µg/mL with less than 10% toxicity to normal cells. In vivo, orthotopic breast tumors treated with US+NIR showed 90% regression, reduced proliferation and angiogenesis, activation of apoptotic and immunogenic cell death pathways, and favorable biocompatibility. Critically, the regimen triggered robust local immune activation, increasing intratumoral CD8

Indexed as

Breast NeoplasmsHydrogelsPhotothermal TherapyAnimalsCatalysisCell Line, TumorFemaleGraphiteHumansMiceReactive Oxygen SpeciesGraphiteHydrogelsReactive Oxygen Speciesbreast cancernear‐infraredpiezocatalytic and photothermal therapyreactive oxygen speciesultrasound

Identifiers

PMID41972422
PMCPMC13334646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.